Abstract
HER2 expression has a prognostic and predictive impact in early breast cancer (BC). HER2-positive BC (score 3+ or 2+ with in situ hybridization (ISH) amplification) are treated with anti-HER2 therapies. HER2-low BC (score 1+ or 2+ without ISH amplification) are less defined and until now, no specific treatment has been provided for this subgroup. We tried to explore the response of HER2-low early BC to neoadjuvant chemotherapy (NAC) according to the HER2 score (1+ or 2+).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
